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Original Article

Phase 3 Trial of 177Lu-Dotatate for Midgut
Neuroendocrine Tumors
J. Strosberg, G. El‑Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra,
P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum,
H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem,
A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed,
E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion,
P. Ruszniewski, D. Kwekkeboom, and E. Krenning, for the NETTER-1 Trial Investigators*

A BS T R AC T
BACKGROUND

Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
This randomized, controlled trial evaluated the efficacy and safety of lutetium-177
(177Lu)–Dotatate in patients with advanced, progressive, somatostatin-receptor–positive
midgut neuroendocrine tumors.

The authors’ full names, academic degrees, and affiliations are listed in the
Appendix. Address reprint requests to Dr.
Strosberg at the Moffitt Cancer Center,
12902 Magnolia Dr., Tampa, FL 33612, or
at jonathan.strosberg@moffitt.org.

METHODS

* A complete list of investigators in the Neuroendocrine Tumors Therapy (NETTER-1)
trial is provided in the Supplementary
Appendix, available at NEJM.org.

We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq
every 8 weeks (four intravenous infusions, plus best supportive care including octreotide
long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (177LuDotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at
a dose of 60 mg every 4 weeks (control group). The primary end point was progressionfree survival. Secondary end points included the objective response rate, overall survival,
safety, and the side-effect profile. The final analysis of overall survival will be conducted
in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here.

N Engl J Med 2017;376:125-35.
DOI: 10.1056/NEJMoa1607427
Copyright © 2017 Massachusetts Medical Society.

RESULTS

At the data-cutoff date for the primary analysis, the estimated rate of progression-free
survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177LuDotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate
was 18% in the 177Lu-Dotatate group versus 3% in the control group (P<0.001). In the
planned interim analysis of overall survival, 14 deaths occurred in the 177Lu-Dotatate
group and 26 in the control group (P = 0.004). Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the
177
Lu-Dotatate group as compared with no patients in the control group, with no evidence
of renal toxic effects during the observed time frame.
CONCLUSIONS

Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and
a significantly higher response rate than high-dose octreotide LAR among patients with
advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival
benefit was seen in an interim analysis; confirmation will be required in the planned
final analysis. Clinically significant myelosuppression occurred in less than 10% of
patients in the 177Lu-Dotatate group. (Funded by Advanced Accelerator Applications;
NETTER-1 ClinicalTrials.gov number, NCT01578239; EudraCT number 2011-005049-11.)
n engl j med 376;2
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wide. Eligible patients were adults who had midgut neuroendocrine tumors that had metastasized
or were locally advanced, that were inoperable,
that were histologically confirmed and centrally
verified, and that showed disease progression
(according to Response Evaluation Criteria in
Solid Tumors [RECIST], version 1.119) on either
computed tomography (CT) or magnetic resonance imaging (MRI) over the course of a maximum period of 3 years during treatment with
octreotide LAR (20 to 30 mg every 3 to 4 weeks
for at least 12 weeks before randomization). Patients were required to have a Karnofsky performance-status score of at least 60 (on a scale
from 0 to 100, with lower numbers indicating
greater disability), a tumor with well-differentiated histologic features, and somatostatin receptors present on all target lesions (as confirmed
by blinded, independent central review). Welldifferentiated histologic features were defined
as a Ki67 index (the percentage of cells that are
positive for Ki67 as determined by immunostaining of the primary tumor) of 20% or less;
tumors were assessed as low-grade if they had a
Ki67 index of 0 to 2%, intermediate-grade if they
had a Ki67 index of 3 to 20%, or high-grade if
they had a Ki67 index of greater than 20%, with
a lower grade indicating a lower rate of proliferative activity. Target lesions were selected from CT
or MRI, and the degree of expression of somatostatin receptors was determined on the basis of
the lesion that had the highest uptake of radiotracer observed on planar somatostatin receptor
scintigraphy within 24 weeks before randomization. All CT and MRI images were reviewed and
evaluated for disease progression (according to
RECIST criteria) and somatostatin receptor expression by independent central reviewers who
were unaware of the treatment assignments.
Key exclusion criteria were a serum creatinine
level of more than 150 μmol per liter (1.7 mg per
deciliter) or a creatinine clearance of less than
50 ml per minute; a hemoglobin level of less
than 8.0 g per deciliter; a white-cell count of less
than 2000 per cubic millimeter; a platelet count
of less than 75,000 per cubic millimeter; a total
bilirubin level of more than 3 times the upper
limit of the normal range; a serum albumin
level of more than 3.0 g per deciliter, unless the
Me thods
prothrombin time value was within the normal
Patients
range; treatment with more than 30 mg of octreoThis international, multicenter, phase 3 trial was tide LAR within 12 weeks before randomization;
conducted at 41 centers in 8 countries world- peptide receptor radionuclide therapy at any time

euroendocrine tumors of the midgut (which is defined as the jejunoileum
and the proximal colon) commonly metastasize to the mesentery, peritoneum, and liver and
are frequently associated with the carcinoid syndrome.1,2 Neuroendocrine tumors of the midgut
represent the most common type of malignant
gastrointestinal neuroendocrine tumors and are
associated with 5-year survival rates of less than
50% among persons with metastatic disease.3,4
First-line systemic therapy usually consists of a
somatostatin analogue for control of both hormonal secretion and tumor growth.5-7 With the
exception of everolimus for the treatment of
nonfunctional neuroendocrine tumors,8 no standard second-line systemic treatment options are
currently available.8,9
Since 1992,10-15 radiolabeled somatostatin analogue therapy (a form of treatment also known as
peptide receptor radionuclide therapy) has shown
considerable promise for the treatment of advanced, well-differentiated neuroendocrine tumors,
a majority of which express high levels of somatostatin receptors to which somatostatin analogues
bind.16 This targeted form of systemic radiotherapy allows the delivery of radionuclides directly to
tumor cells. Initial efficacy results were based on
very high doses of 111In-DTPA0-octreotide,11 but
more promising results were subsequently found
with 90Y-DOTA0-Tyr3–octreotide (90Y-DOTATOC)17
and with 177Lu-DOTA0-Tyr3–octreotate (177LuDotatate).12 Lutetium-177 (177Lu) is a beta- and
gamma-emitting radionuclide with a maximum
particle range of 2 mm and a half-life of 160
hours.18 In a single-group trial of 177Lu-Dotatate
involving 310 patients who had gastroenteropancreatic neuroendocrine tumors, complete tumor
remissions occurred in 2% of the patients and
partial tumor remissions in 28%.12 The median
progression-free survival was 33 months.
We report here results from the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial,
which evaluated the efficacy and safety of 177LuDotatate as compared with high-dose octreotide
long-acting repeatable (LAR) in patients with
advanced, progressive, somatostatin-receptor–
positive midgut neuroendocrine tumors.
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before randomization; and any surgery, liver- Trial Oversight
directed transarterial therapy, or chemotherapy This trial was sponsored by Advanced Accelerawithin 12 weeks before randomization.
tor Applications and was designed by Advanced
Accelerator Applications in collaboration with the
Trial Design
last two authors. The trial protocol was approved
In this open-label, phase 3 trial, we randomly by the investigational review board or independent
assigned patients, in a 1:1 ratio, to receive 177Lu- ethics committee at each participating instituDotatate plus best supportive care, consisting of tion. Contract research organizations monitored
octreotide LAR at a dose of 30 mg every 4 weeks the trial and collected, compiled, maintained, and
for symptom control (177Lu-Dotatate group) or to analyzed the data. The trial was performed in acreceive high-dose octreotide LAR, at a dose of cordance with the principles of the Declaration of
60 mg every 4 weeks (control group). Random- Helsinki, International Conference on Harmoni
ization was performed with the use of a central- sation Good Clinical Practice guidelines, and all
ized permuted block (block size of 4) randomiza- applicable regulations. All the patients provided
tion scheme, with stratification according to the written informed consent. An independent data
highest tumor uptake score on somatostatin re- and safety monitoring board oversaw the conduct
ceptor scintigraphy (grade 2, 3, or 4 on a scale of the trial. The first draft of the manuscript was
ranging from 0 [no uptake by tumor] to 4 [very prepared by the first author with assistance from
intense uptake by tumor] with higher grades in- a professional medical writer funded by the spondicating a higher level of expression of soma- sor. All the authors contributed to subsequent
tostatin receptors)12 and according to the length drafts and agreed to submit the manuscript for
of time that a patient had been receiving a con- publication. All the authors vouch for the accustant dose of octreotide (≤6 months or >6 months). racy and completeness of the data and the analyIn the 177Lu-Dotatate group, 7.4 GBq (200 mCi) sis and for the fidelity of the trial to the protocol.
177
of Lu-Dotatate was infused intravenously over The protocol and statistical analysis plan are availa period of 30 minutes. Patients received four able with the full text of this article at NEJM.org.
infusions every 8 weeks (cumulative radioactivity,
29.6 GBq [800 mCi]) unless unacceptable toxic End Points and Assessments
effects occurred, centrally confirmed disease The primary end point was progression-free surprogression (according to RECIST) was present vival, which was defined as the time from ranon imaging, the patient was unable or unwilling domization to documented disease progression
to adhere to trial procedures, the patient with- (as evaluated by independent central review by
drew consent, or the patient died. For renal radiologists who were unaware of the treatment
protection, an intravenous amino acid solution assignments) or death from any cause. Secondary
(Aminosyn II 10% [21.0 g of lysine and 20.4 g end points included the objective response rate,
of arginine in 2 liters of solution] or VAMIN-18 overall survival (defined as the time from ran[18 g of lysine and 22.6 g of arginine in 2 liters domization to death from any cause), safety, and
of solution]) was administered concomitantly for the side-effect profile. An objective tumor assessat least 4 hours, starting 30 minutes before infu- ment on CT or MRI was performed every 12 weeks
sion of the radiopharmaceutical. In the 177Lu- after the date of randomization in both treatment
Dotatate group, patients continued to receive groups. The treatment was considered to have
supportive care with octreotide LAR, which was failed if a patient had progressive disease on
administered intramuscularly at a dose of 30 mg imaging, according to central assessment with the
approximately 24 hours after each infusion of use of RECIST criteria, and patients with treat177
Lu-Dotatate and then monthly after completion ment failure proceeded directly to the long-term
of all four treatments. In the control group, follow-up phase. We calculated the response rate
octreotide LAR at a dose of 60 mg was adminis- as the percentage of patients who had a response
tered intramuscularly every 4 weeks. In both treat- according to RECIST (sum of partial responses
ment groups, patients were allowed to receive and complete responses). Definitions of all resubcutaneous rescue injections of octreotide in sponse categories are provided in the protocol.
Safety was assessed (at least every 2 to 12 weeks,
the event of hormonal symptoms (i.e., diarrhea
or flushing) associated with their carcinoid syn- depending on the phase of the trial [treatment
phase or follow-up phase] and treatment group)
drome.
n engl j med 376;2
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means of the Kaplan–Meier method. Objective
response rates and corresponding 95% confidence intervals were calculated for each treatment group and were compared with the use of
Fisher’s exact test. Survival curves were compared with the use of an unstratified log-rank
test and were tested against the null hypothesis.
Hazard ratios were estimated with the use of an
unstratified Cox proportional-hazards model.

Statistical Analysis

We calculated the required number of patients
for the trial assuming that the median progression-free survival would be 30 months in the
177
Lu-Dotatate group and 14 months in the control group, the study would have 90% nominal
power at an alpha level of 5%, and the prespecified enrollment period and follow-up period for
both groups would be 18 months. On the basis
of those assumptions, we calculated that we
needed a sample of 124 patients, and the analysis of the primary end point was planned to be
conducted after at least 74 events of disease
progression or death that were centrally confirmed and could be evaluated had occurred.
However, the sample size of the trial was adjusted to 230 patients to enable us to detect a
statistically significant and clinically relevant
difference between the two treatment groups in
overall survival as a secondary end point. This
calculation was based on the assumption that
the median overall survival would be 50 months
in the 177Lu-Dotatate group and 32 months in the
control group, with 80% nominal power at an
alpha level of 5%, and a prespecified enrollment
period of 18 months and a long-term follow-up
period of 60 months. A prespecified interim
analysis of overall survival was conducted at the
time of the analysis of progression-free survival.
The final analysis of overall survival is planned
to be performed either after 158 deaths have occurred or 5 years after the last patient underwent
randomization, whichever occurs first.
All patients who underwent randomization
were included in the analyses of efficacy, demographics, and baseline characteristics. The safety population, which comprised all patients who
underwent randomization and received at least
one dose of trial treatment, was used for all
safety analyses. The median point estimate and
95% confidence interval for progression-free
survival and overall survival were estimated by
128

n engl j med 376;2

R e sult s
Patients

From September 2012 through mid-January
2016, a total of 229 patients underwent randomization at 41 sites (27 sites in Europe and 14 in
the United States); 221 of the 229 patients who
underwent randomization received at least one
dose of trial treatment, including 111 patients in
the 177Lu-Dotatate group and 110 in the control
group (safety population) (Fig. S1 in the Supplementary Appendix). The demographic and clinical characteristics of the patients were well balanced between the two treatment groups; the
ileum was the primary tumor site in a majority
of patients (73%), and most patients presented
with metastases in the liver (83%), the lymph
nodes (62%), or both, typically in the mesentery
or retroperitoneum (Table 1, and Table S1 in the
Supplementary Appendix). The treatment groups
were well balanced with respect to tumor grade
(low-grade [grade 1] Ki67 proliferation index in
66% of patients in the 177Lu-Dotatate group and
in 72% in the control group) and with respect to
the highest uptake of tumor somatostatin radiotracer (high-grade [grade 4] uptake in 61% of
patients in the 177Lu-Dotatate group and in 59%
of patients in the control group). Serum chromogranin A levels and 5-hydroxyindoleacetic acid
levels in a 24-hour urine specimen were similar
in the two treatment groups. Approximately
80% of the patients had undergone previous
surgical resection (78% in the 177Lu-Dotatate
group and 82% in the control group), and nearly
half the patients had undergone a previous form
of systemic therapy other than somatostatin
analogue therapy (41% of patients in the 177LuDotatate group and 45% in the control group).
Efficacy

At the time of the data cutoff for the primary
analysis (July 24, 2015), 23 events of disease
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Table 1. Demographic and Baseline Clinical Characteristics of All Patients Who Underwent Randomization.*
177Lu-Dotatate

Group
(N = 116)

Characteristic

Control Group
(N = 113)

Sex — no. (%)
Male

63 (54)

53 (47)

Female

53 (46)

60 (53)

Age — yr

63±9

64±10

Body-mass index†

25±5

26±7

3.8

4.8

Ileum

86 (74)

82 (73)

Small intestine, not otherwise specified

Median time since diagnosis — yr
Primary tumor site — no. (%)

11 (9)

12 (11)

Midgut, not otherwise specified

9 (8)

7 (6)

Jejunum

6 (5)

9 (8)

Right colon

3 (3)

1 (1)

Appendix

1 (1)

2 (2)

Liver

97 (84)

94 (83)

Lymph nodes

77 (66)

65 (58)

Mesentery

17 (15)

8 (7)

Bone

13 (11)

12 (11)

Other

15 (13)

10 (9)

Site of metastasis — no. (%)

Peritoneum
Lungs
Ovaries

7 (6)

10 (9)

11 (9)

5 (4)

1 (1)

9 (8)

Somatostatin receptor scintigraphy, Krenning scale
— no. (%)‡
Grade 2

11 (9)

12 (11)

Grade 3

34 (29)

34 (30)

Grade 4

71 (61)

67 (59)

* Plus–minus
	
values are means ±SD. Percentages may not sum to 100 because of rounding.
†	The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡	The Krenning scale ranges from grade 0 (no uptake by tumor) to grade 4 (very intense uptake by tumor), with higher
grades indicating a higher level of expression of somatostatin receptors. The highest grade per patient was reported.

progression or death had occurred in the 177LuDotatate group and 68 such events had occurred
in the control group. The estimated rate of progression-free survival at month 20 was 65.2%
(95% confidence interval [CI], 50.0 to 76.8) in
the 177Lu-Dotatate group and 10.8% (95% CI, 3.5
to 23.0) in the control group. The median progression-free survival had not yet been reached
in the 177Lu-Dotatate group and was 8.4 months
(95% CI, 5.8 to 9.1) in the control group (hazard
ratio for disease progression or death with 177LuDotatate vs. control, 0.21; 95% CI, 0.13 to 0.33;
n engl j med 376;2

P<0.001), which represented a 79% lower risk of
disease progression or death in the 177Lu-Dotatate group than in the control group (Fig. 1A).
Consistent treatment benefits associated with
177
Lu-Dotatate were observed irrespective of
stratification factors and prognostic factors,
which included levels of radiotracer uptake on
somatostatin receptor scintigraphy, tumor grade,
age, sex, and tumor marker levels (Fig. 1C).
In addition to the analysis of progression-free
survival, we performed a planned interim analysis of overall survival. A total of 14 deaths in the
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B Overall Survival (Interim Analysis)

100

Overall Survival
(% of patients)

Progression-free Survival
(% of patients)

A Progression-free Survival

of

10

Control
0

5

10

15

20

25

0

30

0

5

Months since Randomization
No. at Risk
177Lu-DOTATATE

group
Control group

116 97
113 80

76
47

59
28

42
17

28
10

10

15

No. at Risk
19
4

12
3

20

25

30

Months since Randomization

3

2

1

0

0

177Lu-DOTATATE

116 108

96

79

64

47

31

21

8

3

0

0

group
Control group

113 103

83

64

41

32

17

5

1

0

0

C Prespecified Subgroup Analysis of Progression-free Survival
Subgroup

Hazard Ratio (95% CI)

Extrahepatic metastases
Yes
No
Alkaline phosphatase
>ULN
≤ULN
Somatostatin receptor expression
Grade <4
Grade 4
5-HIAA
>2× ULN
≤2× ULN
Chromogranin A
>2× ULN
≤2× ULN
Tumor grade
ENETS Grade 2
ENETS Grade 1
Sex
Male
Female
Age
>65 yr
≤65 yr
Overall

0.20 (0.12–0.35)
0.15 (0.04–0.50)
0.21 (0.09–0.49)
0.19 (0.11–0.35)
0.23 (0.12–0.41)
0.18 (0.08–0.39)
0.15 (0.08–0.29)
0.19 (0.06–0.55)
0.19 (0.09–0.27)
0.11 (0.01–0.87)
0.15 (0.07–0.34)
0.24 (0.13–0.44)
0.24 (0.12–0.45)
0.17 (0.08–0.35)
0.24 (0.12–0.48)
0.20 (0.10–0.38)
0.21 (0.13–0.33)
0.00

0.25

0.50

177Lu-DOTATATE

0.75

1.00

Better

1.25

1.50

Control Better

Figure 1. Progression-free Survival and Overall Survival.
Panel A shows the results of the Kaplan–Meier analysis of progression-free survival as assessed by independent central reviewers who
were unaware of the treatment assignments, and Panel B the results of the planned interim analysis of overall survival. Tick marks in
Panel A represent data censored at the last time the patient was known to be alive and without disease progression and tick marks in
Panel B represent data censored at the last time the patient was known to be alive. Panel C shows the effect of trial treatment on progression-free survival in prespecified subgroups. European Neuroendocrine Tumor Society (ENETS) grade 1 indicates a low-grade tumor, and ENETS grade 2 indicates an intermediate-grade tumor. The 177Lu-Dotatate group received 177Lu-Dotatate at a dose of 7.4 GBq
every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg). The control group received octreotide LAR alone administered intramuscularly at a dose of 60 mg every
4 weeks. 5-HIAA denotes 5-hydroxyindoleacetic acid, CI confidence interval, and ULN upper limit of the normal range.
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Table 2. Objective Tumor Response.*
Response Category

177Lu-Dotatate

Group
(N = 101)

Complete response — no. (%)

Control Group
(N = 100)

1 (1)

0

17 (17)

3 (3)

No. with response

18

3

Rate — % (95% CI)

18 (10–25)

3 (0–6)

Partial response — no. (%)

P Value†

Objective response
<0.001

*	The objective response rate was defined as the percentage of patients who had a response according to Response
Evaluation Criteria in Solid Tumors (RECIST) (sum of partial responses and complete responses). Patients for whom
no post-baseline computed tomography (CT) or magnetic resonance imaging (MRI) scans or central response data
were available (15 patients in the 177Lu-Dotatate group and 13 patients in the control group) were excluded from this
analysis (trial is still ongoing).
†	The P value was calculated with the use of Fisher’s exact text.

Table 3. Overview of Adverse Events (Safety Population).*
177Lu-Dotatate

Group
(N = 111)

Event

Control Group
(N = 110)

P Value†

number of patients (percent)
Adverse event
Any

106 (95)

95 (86)

0.02

95 (86)

34 (31)

<0.001

Any

29 (26)

26 (24)

0.76

Related to treatment

10 (9)

1 (1)

0.01

Because of any adverse event

7 (6)

10 (9)

0.46

Because of adverse event related to treatment

5 (5)

0

0.06

Related to treatment
Serious adverse event

Withdrawal from trial because of adverse event

* 	The safety population included all patients who underwent randomization and received at least one dose of trial treatment.
†	P values were calculated with the use of Fisher’s exact text.

Lu-Dotatate group and 26 deaths in the control group were observed, which represented
an estimated risk of death that was 60% lower
in the 177Lu-Dotatate group than in the control
group (hazard ratio for death with 177Lu-Dotatate
group vs. control, 0.40; P = 0.004) (Fig. 1B). The
O’Brien–Fleming threshold for significance at
the first interim analysis was 0.000085. Data were
not sufficiently mature to provide an estimate of
the median overall survival in either treatment
group. Within the population of patients who
could be evaluated for tumor response (201 patients), the total number of complete and partial
responses was 18 in the 177Lu-Dotatate group
and 3 in the control group, which corresponded
to response rates of 18% and 3%, respectively
(P<0.001) (Table 2).
177
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A majority of patients (77%) in the 177Lu-Dotatate
group received all four infusions of 177Lu-Dotatate.
A total of eight patients required dose reduction.
Details regarding patient exposure to treatment
are presented in Table S2 in the Supplementary
Appendix.
In total, 201 patients (95% of patients in the
177
Lu-Dotatate group and 86% of patients in the
control group) had at least one adverse event during the trial. Adverse events that were considered
by the investigator to be related to trial treatment
occurred in 129 patients: 95 patients (86%) in the
177
Lu-Dotatate group and 34 patients (31%) in
the control group (Table 3). Adverse events that
occurred after the start of treatment and subsequently led to premature withdrawal from the
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Table 4. Adverse Events (Safety Population).*
Event

177Lu-Dotatate

Group
(N = 111)

Any Grade

Grade 3 or 4

Control Group
(N = 110)
Any Grade

P Value†

Grade 3 or 4

Any Grade

0.01

number of patients (percent)
Any adverse event

105 (95)

46 (41)

92 (84)

36 (33)

Gastrointestinal disorders
Nausea

65 (59)

4 (4)

13 (12)

2 (2)

<0.001

Vomiting

52 (47)

8 (7)

11 (10)

1 (1)

<0.001

Abdominal pain

29 (26)

3 (3)

29 (26)

6 (5)

1.00

Diarrhea

32 (29)

3 (3)

21 (19)

2 (2)

0.11

Distension

14 (13)

0

15 (14)

0

0.84

Fatigue or asthenia

44 (40)

2 (2)

28 (25)

2 (2)

0.03

Edema peripheral

16 (14)

0

8 (7)

0

0.13

28 (25)

2 (2)

1 (1)

0

<0.001

General disorders

Blood disorders
Thrombocytopenia
Anemia

16 (14)

0

6 (5)

0

0.04

Lymphopenia

20 (18)

10 (9)

2 (2)

0

<0.001

Leukopenia

11 (10)

1 (1)

1 (1)

0

0.005

Neutropenia

6 (5)

1 (1)

1 (1)

0

0.12

32 (29)

2 (2)

22 (20)

1 (1)

0.16

20 (18)

0

9 (8)

3 (3)

0.04

Headache

18 (16)

0

5 (5)

0

0.007

Dizziness

12 (11)

0

6 (5)

0

0.22

14 (13)

1 (1)

10 (9)

0

0.52

12 (11)

0

2 (2)

0

0.01

12 (11)

0

6 (5)

0

0.22

Musculoskeletal disorders
Musculoskeletal pain
Nutrition disorders
Decreased appetite
Nervous system disorders

Vascular disorders
Flushing
Skin disorders
Alopecia
Respiratory disorders
Cough

*	Shown are all adverse events that were reported in at least 10% of the patients in the 177Lu-Dotatate group, with the
exception of neutropenia, which was reported in less than 10% of the patients in the 177Lu-Dotatate group. For the individual events, the system organ classes in the Medical Dictionary for Regulatory Activities (MedDRA) hierarchy are shown
in bold and are followed by the MedDRA preferred terms (not bold). The safety population included all patients who
underwent randomization and received at least one dose of trial treatment.
†	P values were calculated with the use of Fisher’s exact text.

trial occurred in 7 patients (6%) in the 177Lu- among patients in the 177Lu-Dotatate group were
Dotatate group and in 10 patients (9%) in the nausea (65 patients [59%]) and vomiting (52 pacontrol group. The most common adverse events tients [47%]). A majority of these cases (in 42 of
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the 65 patients [65%] and in 38 of the 52 patients
[73%], respectively) were attributable to amino
acid infusions that were performed concurrently
with administration of 177Lu-Dotatate, and the
events resolved once the infusions were completed. Other common adverse events in the
177
Lu-Dotatate group included fatigue or asthenia, abdominal pain, and diarrhea; however, a
majority of the patients in whom these events
were reported (≥97%) had events of grade 1 or 2
(Table 4). Among patients in the control group,
the most common adverse events were gastrointestinal disorders and fatigue or asthenia. The
rates of grade 3 or 4 adverse events were similar
in the two groups; however, grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia were
reported in 1%, 2%, and 9% of patients, respectively, in the 177Lu-Dotatate group versus no patients in the control group. These hematologic
events were transient (Fig. S2 in the Supplementary Appendix). No evidence of renal toxic effects
was seen among patients in the 177Lu-Dotatate
group (Fig. S3 in the Supplementary Appendix)
during the observed time frame (median duration of follow-up, 14 months).
The myelodysplastic syndrome is an adverse
event of potential interest in this trial, given the
long-term risk of the myelodysplastic syndrome
or acute leukemia that has been reported previously in approximately 2% of patients.20,21 Before
the data cutoff date, one patient in the 177LuDotatate group of our trial (0.9%) who had a
history of monoclonal gammopathy of unknown
clinical significance had cytopenias; the patient
subsequently underwent a bone marrow biopsy
that revealed histologic changes consistent with
the myelodysplastic syndrome that were considered by the investigator to be possibly related to
the investigational therapy.

The median progression-free survival was 8.4
months in the control group and had not yet
been reached in the 177Lu-Dotatate group. A subgroup analysis showed consistent benefit across
major subgroups. The response rate of 18% in
the 177Lu-Dotatate group (as compared with 3%
in the control group) is also notable given that
response rates above 5% have not been observed
in large randomized clinical trials of other systemic therapies in this patient population.22-25
Although our trial has not yet reached the point
at which the median overall survival can be calculated, the results of the interim analysis suggest longer overall survival with 177Lu-Dotatate
than with high-dose octreotide LAR. The final
analysis of overall survival is planned to be performed either after 158 deaths have occurred or
5 years after the last patient underwent randomization, whichever occurs first. 177Lu-Dotatate,
when administered concomitantly with a renalprotective agent, was associated with low rates
of grade 3 or 4 hematologic toxic effects and
showed no evidence of renal toxic effects over
the trial time frame (median duration of followup, 14 months).
Radiolabeled somatostatin analogues provide
a means of delivering targeted radiation with a
high therapeutic index to tumors that express
somatostatin receptors.12-15,20,21,26-28 Data from nonrandomized trials of 177Lu-Dotatate have consistently shown high response rates and long durations of median progression-free survival in
heterogeneous patient populations with gastroenteropancreatic neuroendocrine tumors.12,26,29,30
The NETTER-1 trial validates these early-phase
data in the context of a prospective, randomized
trial.
In summary, 177Lu-Dotatate resulted in marked
ly longer progression-free survival than high-dose
octreotide LAR and was associated with limited
acute toxic effects in a population of patients
Discussion
who had progressive neuroendocrine tumors that
In this randomized, phase 3 trial involving pa- originated in the midgut.
tients with progressive midgut neuroendocrine
Presented in part at the annual meeting of the American Socitumors, treatment with 177Lu-Dotatate resulted ety of Clinical Oncology, Chicago, June 3–7, 2016.
Supported by Advanced Accelerator Applications.
in a risk of progression or death that was 79%
Disclosure forms provided by the authors are available with
lower than the risk associated with high-dose the full text of this article at NEJM.org.
octreotide LAR. The estimated rate of progresWe thank the participating patients and their families; the
sion-free survival at month 20 was 65.2% (95% global network of research nurses, trial coordinators, and operations staff for their contributions; and the investigators whose
CI, 50.0 to 76.8) in the 177Lu-Dotatate group and patients were enrolled in this trial (a list of the investigators can
10.8% (95% CI, 3.5 to 23.0) in the control group. be found in the Supplementary Appendix).
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